SC 13G: Monopar Therapeutics
Ticker: MNPR · Form: SC 13G · Filed: 2024-10-28T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Monopar Therapeutics.
Risk Assessment
Risk Level: low
From the Filing
0001104659-24-111584.txt : 20241028 0001104659-24-111584.hdr.sgml : 20241028 20241028060028 ACCESSION NUMBER: 0001104659-24-111584 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20241028 DATE AS OF CHANGE: 20241028 GROUP MEMBERS: ALEXION PHARMACEUTICALS, INC. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-94081 FILM NUMBER: 241398269 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 SC 13G 1 tm2426761d1_sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Monopar Therapeutics Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 61023L207 (CUSIP Number) October 23, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rule 13d-1(b) x Rule 13d-1(c) ¨ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Schedule 13G CUSIP No. 61023L207 1. Name of Reporting Person AstraZeneca PLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) x  (Joint filers) 3. SEC Use Only 4. Citizenship or Place of Organization United Kingdom Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 387,329 shares 1 6. Shared Voting Power 0 shares 7. Sole Dispositive Power 387,329 shares 2 8. Shared Dispositive Power 0 shares 9. Aggregate Amount Beneficially Owned by Each Reporting Person 387,329 shares 3 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ 11. Percent of Class Represented by Amount in Row (9) 9.9% 4 12. Type of Reporting Person (See Instructions) CO 1 Represents shares directly held by Alexion Pharmaceuticals, Inc., a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and Alexion Pharmaceuticals, Inc. (collectively, the “Reporting Persons”) may each be deemed to have sole voting and dispositive power over the shares. 2 See footnote 1. 3 See footnote 1. 4 The percentage ownership was calculated based on a total of 3,912,408 shares of common stock, $0.001 par value (“Common Stock”), of Monopar Therapeutics Inc. (the “Issuer&rdquo